歌礼制药(01672)2018年作为港股“18A第一股”上市,专注抗病毒、代谢性疾病(如非酒精性脂肪性肝炎MASH)及肿瘤药物研发。上市初期市值曾达157亿港元,后因核心丙肝药物戈诺卫市场竞争失利、管线收缩等,2024年上半年营收归零,市值一度跌至不足8亿港元,股价触及历史低点0.76港元。2024年,歌礼制药经历战略调整,砍掉6条非核心管线,聚焦MASH与肥胖症药物研发。财报显示,公司2024年...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.